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In medicine, a syndrome denotes that certain criteria
or clinical conditions are satisfied; it is not an etiologic
diagnosis. Severe acute respiratory syndrome (SARS)
has emerged recently as a major public health threat,
but is it a new disease or just a synonym for acute lung
injury (ALI) or acute respiratory distress syndrome
(ARDS)?
In 1967, Ashbaugh and colleagues1 first described
a syndrome of acute respiratory distress in adults that
closely resembled respiratory distress in infants. These
authors detailed the clinical course of 12 patients
treated in Denver for respiratory failure who did not
respond to usual therapeutic modalities of respiratory
support. The patients had an acute onset of tachypnea,
hypoxemia, panlobular infiltration on chest X-ray, and
loss of lung compliance. The investigators thought the
syndrome resulted from surfactant deficiency, and
found positive end-expiratory pressure helpful in
treating the atelectasis and hypoxemia. They also
thought that corticosteroids were helpful for patients
in whom the syndrome resulted from fat embolism. In
1971, the same investigators coined the name adult
respiratory distress syndrome.2
Since its initial description in 1967, ARDS has been
the focus of intense scrutiny and attempts to improve
outcomes. The European-American Consensus
Conference on ARDS developed a uniform definition
for ARDS to aid clinical trial design.3 The conference
attendees agreed that ARDS was a severe form of ALI,
and recommended that the syndrome be called “acute”,
rather than “adult”, respiratory distress syndrome.
They defined ALI and ARDS as being characterized by
an acute onset, bilateral infiltration on chest X-ray,
hypoxemia, and no evidence of left atrial hypertension
(pulmonary artery occlusion pressure 18 mmHg). The
degree of hypoxemia is more severe in ARDS (partial
arterial oxygen pressure [PaO2]:fractional inspired
oxygen [FIO2] ratio ) 200 mmHg) than ALI (PaO2/
FIO2 ) 300 mmHg). The severity of ARDS can be
scored (Murray lung injury score) using several easily
measured clinical variables.4 ARDS occurs in various
clinical settings with direct or indirect respiratory insults
(e.g. acute pneumonia or pneumonitis, aspiration of
gastric content, near-drowning, acute pancreatitis,
sepsis syndrome, massive emergency transfusions,
environmental toxin exposure), severe multiple trauma
(e.g. pulmonary contusion, multiple long bone fracture
with fat embolism syndrome), or extensive tissue
injury or destruction during major surgical interven-
tions (e.g. cardiac surgery with prolonged extra-
corporeal bypass). The mortality rate from ARDS
remains high (45–92%), but outcomes have improved
over the last decade.5–15
How did the term SARS originate? Before the mid-
1990s, the US Centers for Disease Control and
Prevention (CDC) and public authorities stipulated
that sentinel hospitals or clinicians should report
suspected or definitively diagnosed cases of respiratory
illness in which there were associated public health
concerns. However, public authorities derived im-
portant information from a rodent-borne hantavirus
infection in 1993: an outbreak of an unexplained
respiratory illness with high mortality occurred in the
US southwest, and the cause was unexpectedly proved
to be hantavirus. This contradicted the previous belief
that human hantavirus infection only caused the
hemorrhagic-fever renal syndrome described in Asia
and Europe. Hence, the US outbreak led to the first
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description of hantavirus pulmonary syndrome (HPS),
identified as a seemingly new human infectious disease
caused by hantavirus variants including Sin Nombre
and Black Creek Canal viruses; HPS has an influenza-
like prodromal stage, but can progress to catastrophic
hemodynamic failure and pulmonary edema.16–21 Thus,
public health authorities understood that the case-
reporting system was inadequate in this setting.
In May 1995, the World Health Assembly amended
international infectious disease regulations, and in
1998, the World Health Organization (WHO)
arranged for 21 countries to conduct a clinical trial of
a new case-reporting system for acute hemorrhagic
fever syndrome, acute diarrhea syndrome, acute neu-
rologic syndrome, acute respiratory syndrome, acute
jaundice syndrome, and other notifiable syndromes.
The term SARS has been used by public health
authorities, especially after 1997, when the world was
concerned with the emergence of a potentially new
influenza pandemic caused by the transmission of a
highly pathogenic H5N1 influenza virus (H5N1/97)
from chicken to humans in Hong Kong.22–24 On
March 15, 2003, worldwide attention was drawn to
cases of a rapidly progressive respiratory illness in
China (Guangdong Province), Hong Kong (Special
Administrative Region), Vietnam, Singapore, and
Canada. Termed SARS by the WHO, attention has
focused on tracking cases, determining a cause, es-
tablishing a laboratory test for diagnosis, evaluating
treatments, and testing infection-control strategies to
prevent further spread. The WHO is spearheading
these efforts in collaboration with the US CDC and
health authorities from several countries, including
those of Canada, China, Germany, Hong Kong,
Singapore, Taiwan, Thailand, the Netherlands, and
Vietnam.
A novel coronavirus was detected in specimens
from several of the patients with SARS, and the virus
was soon sequenced25 and found to fulfill Koch’s
postulates.26 Thus, a clarification on ARDS and SARS
should be made to avoid further misunderstanding.
To my knowledge, ALI, ARDS and SARS all imply the
occurrence of acute lung injury resulting from direct
or indirect respiratory insult. SARS is a qualitative term
that does not define the severity of lung injury and
oxygenation dysfunction, whereas ALI and ARDS are
quantitative terms that clearly define the severity of
lung injury and oxygenation dysfunction. Hence,
coronavirus infection could provoke SARS, but SARS
is not always characterized by coronavirus infection.
In this issue of the Journal of the Chinese Medical
Association, Chen et al report data from a retrospective
analysis of 67 patients with the following signs or
symptoms: acute onset of fever above 38$C; cough
or dyspnea; and positive reverse transcriptase-
polymerase chain reaction, or antibodies, for coro-
navirus. These investigators found that age greater
than 65 years, diabetes mellitus, and elevated lactate
dehydrogenase levels at admission, were independent-
ly associated with the development of ARDS.27 The
findings from this case-series study warrant ex-
trapolation to disease management in the clinical
practice setting and to case stratification in prospective,
randomized controlled trials. Further cohort studies
are impracticable and, because of ethical issues, should
not, and cannot, be undertaken to assess risk factors
associated with the development of ARDS.
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